Cancer Care

Graphic: Cancer Care Banner
 

 

Lung / Esophageal / Thoracic Cancer Clinical Trials

A clinical trial is one of the final steps in a long and careful cancer research process that is looking for better ways to prevent, diagnose, or treat cancer. Clinical trials test new medical approaches in patients with cancer, and are important to developing new treatments for cancer. Many of the "standard treatments" that patients with cancer receive today were developed based on the results of previous clinical trials.

The following is a list of clinical trials with which this cancer care program is currently involved. Talk to your doctor to find out if a clinical trial is right for you.

Esophagus Clinical Trials
A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients With Esophageal Cancer Who Are Treated Without Surgery
Esophagus
R0436
Hartford
Feasibility of a Creative Writing Intervention in an Advanced Cancer Population: A single arm, consecutive cohort study
Esophagus
D15113
Vergo
Randomized Phase II Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas
Esophagus
EA2142
Hourdequin
Randomized Study of Early Palliative Care Integrated with Standard Oncology Care versus Standard Oncology Care Alone in Patients with Incurable Lung or Non-Colorectal Gastrointestinal Malignancies
Esophagus
A221303
Cullinan
Reducing Disparities in Health for Vulnerable Populations in NH and VT: Journey Forward Cancer Survivor Care Planning in the Rural Northeast
Esophagus
FED11061
Pace
Lung Clinical Trials
A Multi-Center, Randomized Open Label Study to Assess the Systemic Exposure, Efficacy, and Safety of 450 Mg Ceritinib Taken with a Low-Fat Meal and 600 Mg Ceritinib Taken with a Low-Fat Meal as Compared with That of 750 Mg Ceritinib Taken in The Fasted State in Adult Patients with ALK Rearranged (ALK-Positive) Metastatic Non-Small Cell Lung Cancer (NSCLC)
Lung
F15016
Lewis
A Multicenter, Randomized, Double-Blind Phase III Trial to Evaluate Efficacy and Safety of BI 695502 plus Chemotherapy versus Avastin plus Chemotherapy in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
Lung
F15148
Dragnev
A Phase 1B Study of Crizotinib in Combination with Pembrolizumab (MK-3475) in Patients with Untreated Advanced ALK-Translocated Non-Small Cell Lung Cancer
Lung
F16056
Shirai
A Phase 1b Open-Label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-Small Cell Lung Cancer
Lung
F16022
Shirai
A Phase I Study of IRX4204 in Combination with Erlotinib in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer
Lung
D16047
Dragnev
A Phase II, Multicenter, Three-Cohort Study of Oral cMET Inhibitor INC280 in Adult Patients with EGFR Wild-Type (wt), Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Received One or Two Prior Lines of Systemic Therapy for Advanced/Metastatic Disease
Lung
F15153
Dragnev
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Lung
E4512
Dragnev
A Phase Ib/II, Open-Label, Multicenter Trial with Oral cMET Inhibitor INC280 Alone and in Combination with Erlotinib versus Platinum/Pemetrexed in Adult Patients with EGFR Mutated, cMET-Amplified, Locally Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) with Acquired Resistance to Prior EGFR Tyrosine Kinase Inhibitor (EGFR TKI)
Lung
F15166
Dragnev
A Randomized Phase 3 Study of LY2835219 plus Best Supportive Care versus Erlotinib plus Best Supportive Care in Patients with Stage IV NSCLC with a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
Lung
F14178
Dragnev
A Randomized, Phase II Trial of Crizotinib Plus Pemetrexed Versus Pemetrexed Monotherapy in ALK-Positive Non-Squamous NSCLC Patients Who Have Progressed Systemically After Previous Clinical Benefit from Crizotinib Monotherapy
Lung
S1300
Fuld
A Randomized, Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC)
Lung
S1403
Fuld
A Single-Arm, Open-Label, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of HM61713 (BI 1482694) in Patients with T790M-Positive Non-Small Cell Lung Cancer (NSCLC) After Treatment with an Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI)
Lung
F15117
Dragnev
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial
Lung
A151216
Dragnev
Evaluation of Appeal and Impact of E-Cigarettes Among Chronic Smokers with Smoking-Related Cancers
Lung
D15154
Sargent
Feasibility of a Creative Writing Intervention in an Advanced Cancer Population: A single arm, consecutive cohort study
Lung
D15113
Vergo
PRIMAL STUDY:A Phase 1b/2, Randomized, Multicenter, Multinational Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined with Docetaxel (PDoc) Compared with Docetaxel (Doc) Alone in Subjects with Recurrent Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Lung
F15072
Dragnev
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin Chemotherapy
Lung
F15167
Dragnev
Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer (Lung-MAP)
Lung
S1400
Dragnev
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin or Carboplatin and Etoposide
Lung
C30610
Russo
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Lung
A081105
Dragnev
Randomized Phase II Study of Maintenance Pemetrexed Versus Observation for Patients with Malignant Pleural Mesothelioma without Progression after First-Line Chemotherapy
Lung
C30901
Dragnev
Randomized Phase II Trial Evaluating the Optimal Sequencing of PD-1 Inhibition with Pembrolizumab (MK-3475) and Standard Platinum-Based Chemotherapy in Patients with Chemotherapy Naive Stage IV Non-Small Cell Lung Cancer
Lung
H16039
Dragnev
Randomized Phase II Trial Of Concurrent Chemoradiotherapy +/- Metformin HCI In Locally Advanced NSCLC
Lung
NRG-LU001
Hartford
Randomized Study of Early Palliative Care Integrated with Standard Oncology Care versus Standard Oncology Care Alone in Patients with Incurable Lung or Non-Colorectal Gastrointestinal Malignancies
Lung
A221303
Cullinan
Reducing Disparities in Health for Vulnerable Populations in NH and VT: Journey Forward Cancer Survivor Care Planning in the Rural Northeast
Lung
FED11061
Pace
Role of Early F-FDG-PET/CT Scan in Predicting Mediastinal Downstaging with Neoadjuvant Chemotherapy in Resectable Stage III A NSCLC
Lung
EA5123
Dragnev
Safety and Efficacy of nab-Paclitaxel (Abraxane) in Combination with Carboplatin as First Line Treatment in Elderly Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study
Lung
F14169
Dragnev
Other Respiratory and Intrathoracic Organs Clinical Trials
A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer
Other Respiratory and Intrathoracic Organs
E2112
Kaufman
Patient and Caregiver Costs Following Hematopoietic Stem Cell Transplantation
Other Respiratory and Intrathoracic Organs
D15165
Meehan
Reducing Disparities in Health for Vulnerable Populations in NH and VT: Journey Forward Cancer Survivor Care Planning in the Rural Northeast
Other Respiratory and Intrathoracic Organs
FED11061
Pace